Johnson & Johnson said the European Commission approved TECVAYLI (teclistamab), a bispecific antibody immunotherapy for multiple myeloma, for use with daratumumab. The approval covers adults with relapsed or refractory disease who have received at least one prior therapy. The regulatory milestone is a positive catalyst for TECVAYLI’s commercial potential in Europe.
Johnson & Johnson said the European Commission approved TECVAYLI (teclistamab), a bispecific antibody immunotherapy for multiple myeloma, for use with daratumumab. The approval covers adults with relapsed or refractory disease who have received at least one prior therapy. The regulatory milestone is a positive catalyst for TECVAYLI’s commercial potential in Europe.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
